Summary & Overview
CPT 78191: Platelet Survival (Platelet Lifespan) Study
CPT code 78191 designates a platelet lifespan (platelet survival) study in which a patient's platelets are drawn, labeled with a radiopharmaceutical, and re‑transfused to monitor platelet kinetics. This specialized nuclear medicine test is important for diagnosing causes of thrombocytopenia and evaluating platelet destruction or functional disorders. Nationally, the procedure has implications for hematology care pathways, utilization monitoring, and payer coverage policies given its specialized nature and use of radiolabeling.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose of the test, typical sites of service, and the common modifiers associated with reporting. The publication summarizes typical billing and coding context, common payer considerations, and operational implications for providers and facilities that perform nuclear platelet survival testing. It also provides benchmarks where available and notes when specific data points are not provided. The content is targeted to billing professionals, clinical program managers, and policy analysts seeking a national perspective on coding, clinical context, and payer coverage patterns for CPT code 78191.
Billing Code Overview
CPT code 78191 describes a diagnostic procedure in which a provider studies platelet lifespan by drawing a blood sample, labeling the patient's platelets with a radiopharmaceutical, and re‑transfusing the labeled platelets to monitor survival over time. This is a nuclear medicine hematology study that assesses platelet kinetics and can help evaluate suspected platelet destruction or dysfunction.
Service Type: Diagnostic nuclear medicine study — platelet survival test
Typical Site of Service: Hospital outpatient department, nuclear medicine department, or specialized diagnostic imaging center
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a middle-aged adult referred to a hematology-nuclear medicine service for evaluation of unexplained thrombocytopenia or suspected platelet survival disorder after standard laboratory testing and peripheral smear evaluation. The patient presents with recurrent mucocutaneous bleeding and a platelet count that is low or of uncertain significance despite prior treatment. The clinical workflow begins with a hematology consultation documenting indications for platelet lifespan testing, review of prior therapies (e.g., corticosteroids, IVIG, splenectomy), and contraindications to radiolabeled blood products. On an outpatient or short-stay basis in a nuclear medicine suite (typical site of service: hospital outpatient department or specialized imaging center), blood is drawn, platelets are separated, labeled with a radiopharmaceutical (commonly Indium-111 or Technetium-99m), and re-transfused to the patient under monitored conditions. Serial imaging and/or blood sampling occur over subsequent hours to days to measure platelet disappearance and calculate lifespan. Results inform diagnosis (immune thrombocytopenia, consumptive disorders, hypersplenism) and guide management such as consideration of splenectomy or alternate therapies. Documentation includes informed consent specific to radiolabeled autologous transfusion, procedural notes of platelet separation and labeling, radiopharmaceutical used, timepoints of reinfusion and imaging/sampling, and interpretation of survival curves in the final report.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 |